Statins are first-line therapy for treating dyslipidemia because of their low-density lipoprotein
cholesterol (LDL-C) lowering efficacy, superior event-reduction data and unrivaled cost …

Primary and secondary prevention protocols aim at reducing the plasma levels of lipids-with
particular reference to low-density lipoprotein cholesterol (LDL-C) plasma concentrations–in …

Importance Additional treatment options are needed for patients who do not achieve
sufficient reduction in low-density lipoprotein cholesterol (LDL-C) level with available lipid …

Importance Guidelines for patients with atherosclerotic cardiovascular disease (ASCVD)
recommend intensive statin therapy and adding nonstatin therapy if low-density lipoprotein …

Background: Rates for recurrent coronary heart disease (CHD) events have declined in the
United States. However, few studies have assessed whether this decline has been similar …

Background Peripheral artery disease (PAD) is associated with increased risk for
atherosclerotic cardiovascular disease (ASCVD) events. Objectives The goal of this study …

Abstract Background Randomized controlled trials (RCTs) of lipid-lowering therapy (LLT) in
which the control groups received placebo without background LLT offer unique insights into …

Background Cardiovascular diseases are the leading cause of death in the United States,
yet a significant proportion of adults at high risk remain undetected by standard screening …

Background Raised low-density lipoprotein cholesterol (LDL-C) in young adulthood (aged
18-39 years) is associated with atherosclerotic cardiovascular disease (ASCVD) later in life …

Importance There is a paucity of data regarding secondary prevention care disparities in
women with premature and extremely premature atherosclerotic cardiovascular disease …